Bristol Myers Squibb 4Q Results

Bristol Myers Squibb 
4Q Revenues: $11.4 billion (-5%)
4Q Earnings: $2.0 billion (-15%)
YTD Revenues: $46.2 billion (0%)
YTD Earnings: $6.3 billion (-10%)
Comments: Results in the quarter were impacted by loss of exclusivity for primarily Revlimid and foreign exchange impacts, partially offset by Opdivo and new product portfolio sales. 
Revenues for in-line products were $8.3 billion in the quarter, up 4%, driven by:
 
Eliquis revenues grew 1% to $2.7 billion. U.S. revenues were $1.7 billion, up 15% driven primarily by demand growth and favorable gross to net adjustments. International revenues were $970 million, a decrease of 17% driven by foreign exchange impacts and lower average net selling prices. 
 
Opdivo revenues increased 11% to $2.2 billion. U.S. revenues were $1.3 billion, up 13% driven by higher demand for our newer metastatic and adjuvant indications, partially offset by declining second-line eligibility across tumors and increased competition. International revenues were $951 million, an increase of 10% driven by higher demand as a result of launches for additional indications and core indications and timing of shipments, partially offset by foreign exchange impacts. 
 
Orencia sales were $913 million, up 6%. Pomalyst/Imnovid sales were up 3% to $877 million. Sprycel and Yervoy sales were up 4% to $578 million and $568 million, respectively.
 
Total new product portfolio sales were $645 million, up 83% in the quarter driven by the launch of Opdualag and higher demand for Abecma and Reblozyl.
 
Revlimid sales were $2.3 billion, down 32% and Abraxane sales were $179 million, down 41% due to loss of exclusivity.